Compare Kroger Co (KR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Neurocrine Biosciences Inc — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Kroger Co is far larger — about 2.5× Neurocrine Biosciences Inc's market cap, and Kroger Co pays a 2.54% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KR | NBIX | |
|---|---|---|
Market Cap | $36.27B | $14.36B |
Volume | 8,301,523 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $185.50 |
52-Week Low | $55.53 | $123.10 |
Typical Hold Time | 108 Days | 23 Days |
Enterprise Value | $57.69B | $14.37B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical outlook. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, though net margin remains thin at 0.73%. Recent earnings beat expectations in Q2 2026, and the company maintains consistent dividends. Analysts are moderately bullish with a $70.62 consensus target, citing digital growth and operational improvements as key drivers.
KR offers value with low P/S (0.26) and stable cash flow generation, but faces risks from competitive pressures and integration challenges from acquisitions. The stock presents opportunity for investors seeking defensive exposure with dividend income, though margin compression and economic sensitivity warrant caution.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
